Sustainability Accounting Standards Board (SASB)

Sustainability Accounting Standards Board (SASB)

Established in 2011, the Sustainability Accounting Standards Board (SASB) is an independent, standards-setting organization dedicated to improving the effectiveness and comparability of corporate disclosure on material environmental, social and governance (ESG) factors.

Beginning with this report, the table below cross-references the SASB Standards for the Pharmaceuticals sector with where that information can be found in this report.

Index # Description Report Location/Direct Answer
ACCESS TO MEDICINES
HC0102-01
Description of initiatives to promote access to health care products in priority countries as defined by the Access to Medicine Index.
HC0102-02
List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP).
DRUG SAFETY & SIDE EFFECTS
HC0102-03
List of products listed in the FDA’s MedWatch Safety Alerts for Human Medical Products (Drugs and Therapeutic Biological Products) database, including those products with Potential Signals of Serious Risks or that have New Safety Information identified by the FDA Adverse Event Reporting System (FAERS).
We do not currently disclose this information. See link below for related information.

Product & Patient Safety
HC0102-04
Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System.
We do not currently disclose this information.
HC0102-05
List of products recalled.
HC0102-06
Description of product stewardship initiatives to promote take-back and redistribution or safe permanent disposal of unused product at the end of its lifecycle. Where applicable: (1) amount of direct funding for such initiatives and (2) amount of product (by weight) accepted for take-back, reuse, or disposal.
SAFETY OF CLINICAL TRIAL PARTICIPANTS
HC0102-07
Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials, including those conducted with third-party clinical research organizations (CROs). Description of processes for obtaining informed consent, of incentives offered to participants, and of any clinical trials terminated due to failure to follow good clinical practice standards.
HC0102-08
Number of FDA Clinical Investigator Inspections of investigators used for clinical trials during the past year that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI).
HC0102-09
Description of legal and regulatory fines and settlements associated with clinical trials in World Bank Low-income and Lower-middle-income Countries (LICs and LMICs) and UN HDI Medium-High Development Countries (MHDCs) that are not captured by the World Bank’s LIC or LMIC rankings. Dollar amount of fines and settlements and a description of corrective actions implemented in response to events.
AFFORDABILITY & FAIR PRICING
HC0102-10
Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period.
We disclose all settlements of ANDAs to the U.S. Federal Trade Commission (FTC) and U.S. Department of Justice, as is required by law.
HC0102-11
Ratio of weighted average rate of net price increases (for all products) to the annual increase in the U.S. Consumer Price Index.
ETHICAL MARKETING
HC0102-12
Description of legal and regulatory fines and settlements associated with false marketing claims, including Federal Food, Drug, and Cosmetic Act violations for off-label marketing prosecuted under the False Claims Act. Dollar amount of fines and settlements and a description of corrective actions implemented in response to events.
HC0102-13
Description of code of ethics governing promotion of off-label use of products, including mechanisms to ensure compliance.
EMPLOYEE RECRUITMENT, DEVELOPMENT & RETENTION
HC0102-14
Description of talent recruitment and retention efforts for scientists and other research and development (R&D) personnel, such as mentorship and career development programs, leadership training, or unique incentive structures.
HC0102-15
Training and development expenditures per full time employee by: (1) expenditures for industry or professional qualification and advanced industry education; (2) all other.
We do not currently disclose this information. See link below for related information.
 
Learning & Development
HC0102-16
Employee turnover by voluntary and involuntary for: Executives/Senior Managers, Mid-level Managers, Professionals, All others (EEO-1 categories: technicians, sales, admin support, service workers).
EMPLOYEE HEALTH & SAFETY
HC0102-17
Total Injury Rate—(Number of recordable injuries and illnesses/Hours Worked)*200,000.
HC0102-18
Days Away, Restricted, or Transferred (DART) rate—(Number of recordable injuries and illnesses resulting in days away from work, restricted work activity, or job transfers/Hours Worked)*200,000.
HC0102-19
Laboratory-acquired infection (LAI) rate—LAIs per 1000 employees in human and animal diagnostic laboratories.
We do not currently disclose this information.
COUNTERFEIT DRUGS
HC0102-20
Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting.
HC0102-21
Description of process for alerting end customers and business partners of potential or known risks associated with counterfeit products.
HC0102-22
Number (and description) of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products.
ENERGY, WATER & WASTE EFFICIENCY
HC0102-23
Total annual energy consumed (gigajoules) and percentage renewable (e.g., wind, biomass, solar).
HC0102-24
Total water withdrawals and percentage in water-stressed regions—High or Extremely High Baseline Water Stress as defined by the WRI Water Risk Atlas; percentage of process water recycled.
HC0102-25
Overall Process Mass Intensity (PMI) and PMI broken down for water and organic solvents, where PMI = quantity of raw materials input (kg) / quantity of active pharmaceutical product (API) output (kg).
We do not currently disclose this information. See link below for related information.

Green & Sustainable Science
HC0102-26
Amount of waste (metric tons); percentage that is recycled, incinerated (including for energy recovery), and landfilled.
CORRUPTION & BRIBERY
HC0102-27
Description of legal and regulatory fines and settlements associated with bribery, corruption, or other unethical business practices, including violations of the Foreign Corrupt Practices Act and those associated with providing kickbacks to physicians. Dollar amount of fines and settlements and a description of corrective actions implemented in response to events.
HC0102-28
Description of code of ethics governing interactions with health care professionals, including mechanisms to ensure employee compliance.
MANUFACTURING & SUPPLY CHAIN QUALITY MANAGEMENT
HC0102-29
Description of FDA enforcement actions taken in response to violations of current good manufacturing practices (cGMP), including: product deemed adulterated, form 483s, suggested recall (Class I, II, III), Warning Letters, Border Alerts, license suspension or revocation, product seizure, Consent Decrees, criminal prosecution. Description of corrective actions implemented in response to actions.
HC0102-30
Percentage of facilities and Tier I suppliers participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients (e.g., APIs, chemical, raw material, excipients, etc.).